SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Goldman Sachs Initiates Coverage On Amneal Pharmaceuticals with Sell Rating, Announces Price Target of $4

Goldman Sachs analyst Nathan Rich initiates coverage on Amneal Pharmaceuticals (NYSE:AMRX) with a Sell rating and announces Price Target of $4.

Benzinga · -
Goldman Sachs analyst Nathan Rich initiates coverage on Amneal Pharmaceuticals (NYSE: AMRX) with a Sell rating and announces Price Target of $4.